6Ckine (6Ckine)
6Ckine (CCL21) is named for its six conserved cysteine residues that distinguish it from typical chemokines that contain only four cysteines. It is highly expressed in the spleen, appendix, and the high endothelial venules of lymph nodes. 6Ckine stimulates chemotaxis of thymocytes and activated T cells and shows preferential activity towards naive T-cells. Unlike most CC chemokines, 6Ckine is not chemotactic for monocytes.
Swiss-Prot Accession Number: O00585
PublicationsPeripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-na?ve schizophrenia (2022) Santiago G. Lago, Jakub Tomasik, Geertje F. Rees, Nitin Rustogi, Javier Vazquez-Bourgon, Sergi Papiol, Paula Suarez-Pinilla, Benedicto Crespo-Facorro, Sabine Bahn Brain Behavior and Immunity
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease (2021) Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Pai RA, Nabel CS, Ruth JR, parente SAT, Arenas DJ, Guilfoyle M, Reddy MP, Weinblatt M, Shadick N, Bower M, Pria AD, Masaki Y, Katz L, Mezey J, Beineke P, Lee D, Tendler C, Kambayashi T, Fossa A, van Rhee F, Fajgenbaum DC Blood Advances
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) Choueiri TK, Atkins MB, Rose TL, Alter RS, Yawen J, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF Investigational New Drugs
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in (2018) Savona M, Pollyea D, Stock W, Oehler V, Schroeder MA, Lancet J, McCloskey J, Kantarigian H, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE Clinical Cancer Research
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM and Butterfield LH J Immunother Cancer
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports